NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (OTCQB: BTTR) (the “Company” or “Better Choice”), an animal health and wellness company, today reported its financial results for the third quarter ended September 30, 2020.

Continue reading here:
Better Choice Company Reports Third Quarter and Year-to-Date 2020 Financial Results

New York City, Nov. 18, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotech company focused on development and commercialization of interferon (IFN) based therapeutics, recently provided a clinical and regulatory update for its AP-003 COVID-19 clinical trials using inhaled interferon alpha 2b.  While recent advancements in vaccines may seem to provide a glimmer of hope for bringing the pandemic to a close, it remains to be seen how safe and effective they will be, and for how long. The importance of life-saving COVID-19 therapeutics is as great ever, and the support for the Company’s use of interferon as a therapeutic for COVID-19 is compelling.

Here is the original post:
What do the Pfizer Vaccine and BetterLife Pharma have in common?

The Company takes first step in its expansion with the addition of a 300,000 sq. ft. facility within Monterey County The Company takes first step in its expansion with the addition of a 300,000 sq. ft. facility within Monterey County

See the article here:
Indus Holdings, Inc. Announces Preliminary Expansion Plans

PRINCETON, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced the appointment of Douglas W. Losordo, MD, FACC, FAHA to the newly created position of Chief Medical Officer, effective immediately. Dr. Losordo, who will report directly to CEO Thijs Spoor, will lead all global clinical development and regulatory initiatives for the Company. Dr. Losordo is an accomplished physician and healthcare executive with more than 20 years of academic research, clinical and corporate experience.

See the original post here:
KBP Biosciences Appoints Douglas Losordo Chief Medical Officer

SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020.

View original post here:
Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of NPM1-mutated acute myeloid leukemia

More here:
Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results

-- Addition of Dr. Raymond Douglas, M.D., PhD, further enhances RVL’s commitment to advancing the clinical and scientific platform supporting Upneeq -- -- Addition of Dr. Raymond Douglas, M.D., PhD, further enhances RVL’s commitment to advancing the clinical and scientific platform supporting Upneeq --

Go here to read the rest:
RVL Pharmaceuticals, Inc. Strengthens Leadership Team as Commercial Launch of Upneeq® Expands

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte’s 2020 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Fortress’ 874 percent revenue growth based on the increase in net product sales from 2016 to 2019 secured its spot in the rankings.

Read the original here:
Fortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row

* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options *

Follow this link:
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

BERKELEY HEIGHTS, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has decided to cancel the Antimicrobial Drug Advisory Committee meeting tentatively scheduled for January 14, 2021 to discuss the New Drug Application (NDA) for Defencath®. When the FDA accepted for filing the Company’s submitted NDA and granted priority review, it set a Prescription Drug User Fee Act (PDUFA) date of February 28, 2021 for the completion of its review for approval of the NDA. The Agency noted that it was planning to hold an advisory committee meeting to discuss the application for Defencath to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI) and that it had not identified any potential review issues at that time. CorMedix has been notified that based on the Agency’s ongoing dialogue with the Company, discussion at an advisory committee is not needed, and it will continue to work on the application with CorMedix during the remainder of the review cycle.

Read the original:
CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting for New Drug Application for Defencath is Not Needed

MIRAMAR, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has closed a $50 million Licensing and Development Agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO).

The rest is here:
Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform

NEW YORK and CUPERTINO, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that an Extraordinary General Meeting of Shareholders of Tenzing (the "Shareholder Meeting") to approve the pending business combination between Tenzing and Reviva (the “Business Combination”) is scheduled to be held on Tuesday, December 8, 2020, at 9:00 a.m., Eastern time. Due to COVID-19 restrictions on in-person meetings, the Shareholder Meeting will be completely virtual and conducted via live webcast.

View original post here:
Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Shareholder Meeting Date to Approve the Business Combination

Last Patient/Last Visit completed on November 13th enabling full clinical database lock

Read the rest here:
AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical Trial; Top-Line Data Readout Expected in First Quarter of 2021

NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 18, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive clinical proof of concept data from its lab-based rapid SARS-CoV-2 3CL protease diagnostic assay in collaboration with its COVID Antigen Test Killer LLC joint venture partner NLC Pharma. The data generated by NLC Pharma in Israel produced 100% sensitivity and 100% specificity in PCR-confirmed positive and negative COVID-19 patient samples. The team is now gathering additional clinical data to submit an emergency use authorization (EUA) to the United States Food & Drug Administration ( FDA) for its lab-based test to be distributed through Todos’ existing lab distribution channels.  Todos is evaluating the best option for the commercialization of its rapid point-of-care version of the 3CL protease assay for the screening and diagnosis of symptomatic and asymptomatic COVID-19 carriers, based on recent updated guidance from the FDA for COVID-19 diagnostic point of care tests.

Original post:
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay

These therapeutics will benefit the treatment of multiple diseases including autoimmune diseases, acute inflammation and cancer These therapeutics will benefit the treatment of multiple diseases including autoimmune diseases, acute inflammation and cancer

Continue reading here:
Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001

A scientific review article “Toll-Like Receptor 9 Agonists in Cancer”, written by Dr Davar Diwakar et al, a prominent immune-oncology research group in Pittsburgh (US), was recently published in the  OncoTargets and Therapy journal discussing and reviewing key players in preclinical studies and ongoing clinical trials of TLR9 agonists. TLR9 is one of the most promising targets for increasing the response and reversing the resistance to current cancer immunotherapies.

The rest is here:
A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in...

WILLIAMSVILLE, N.Y., Nov. 18, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that Chief Executive Officer, James A. Mish, will speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 11:50 a.m. EST. The virtual conference is a forum for objective first-hand updates on both marketed and emerging products across the spectrum of the cannabis industry focusing on consumer, technology, and healthcare.

See the rest here:
22nd Century Group CEO James A. Mish to Speak at Cowen 2020 Boston Cannabis Conference

NEW YORK, NY and SAN DIEGO, CA, Nov. 18, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- As previously announced, during April 2020, Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga”) and Aegea Biotechnologies, Inc. (“Aegea”) have entered into a collaboration agreement to develop COVID-19 (novel coronavirus) assays. Aegea has made substantial progress in designing and developing two different, next generation assays for SARS-CoV-2.

Read the original post:
Tauriga Sciences Inc. Updates Shareholders on Progress Pursuant to the Collaboration Agreement with Aegea Biotechnologies Inc. for New COVID-19...

-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce’s PD-1 inhibitor, JTX-4014-

Go here to see the original:
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism

NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be participating in the Jefferies Virtual London Healthcare Conference, which is being held November 17-19. Details of the presentation are as follows:

See the original post here:
Chiasma to Participate in the Jefferies Virtual London Healthcare Conference